Evidence map›Paper›PMID 40247832›Full record

ArticlePeerJ2025

Changes in the spectrum of kidney diseases: a 14-year single-center retrospective renal biopsy study from southeast China.

Zishan Lin, Shidong Xie, Wenfeng Wang, Tao Hong, Bingjing Jiang, Caiming Chen, Xuan Tao, Dewen Jiang, Jianxin Wan, Hong Chen and 1 more

Abstract read
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zishan Lin *Department of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Shidong Xie *Department of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Wenfeng WangDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Tao HongDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Bingjing JiangDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Caiming ChenDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xuan TaoDepartment of Pathology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Dewen JiangDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jianxin WanDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Hong ChenDepartment of Pathology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yanfang XuDepartment of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Kidney disease has become a significant public health issue. Socioeconomic improvements and environmental changes in China have influenced the kidney disease spectrum. This study aims to examine the changing spectrum of biopsy-confirmed kidney diseases in a single center from southeastern China and explore their clinical-pathological correlations. Methods: Patients who underwent renal biopsy at the First Affiliated Hospital of Fujian Medical University from January 2010 to December 2023 were included in this retrospective study. Clinicopathological data were collected and analyzed. Results: 2,832 patients were enrolled. Primary glomerular diseases accounted for the majority of kidney diseases (69.0%), followed by secondary glomerular diseases, tubulointerstitial diseases, and others. Among primary glomerular diseases, membranous nephropathy (MN) was the most prevalent (34.9%), followed closely by IgA nephropathy (IgAN) (34.5%) and minimal change disease (18.5%), with an increasing trend for MN. For secondary glomerular diseases, lupus nephritis (34.3%), diabetic nephropathy (DN) (24.8%), and hepatitis B virus-associated nephropathy (HBVN) (9.0%) were the most common. HBVN showed a significant decrease, while DN increased annually. Nephrotic syndrome (NS) was the most frequent indication for renal biopsy (40.3%), followed by progressive chronic kidney disease (22.4%). MN (47.2%) was the leading pathology in NS, and IgAN (51.6%) was predominant in patients with proteinuria and hematuria. Conclusions: The spectrum of kidney disease has changed within the last 14 years. The relative frequency of MN and DN increased significantly, while that of HBVN decreased significantly. These findings highlight the need for ongoing public health efforts tailored to the changing spectrum of kidney diseases.

Indexed as

KidneyKidney DiseasesAdolescentAdultAgedBiopsyChildChinaFemaleGlomerulonephritis, IGAGlomerulonephritis, MembranousHumansMaleMiddle AgedPrevalenceRetrospective StudiesDiabetic nephropathyKidney diseaseMembranous nephropathyNephrotic syndromeRenal biopsy

Identifiers

PMID40247832
PMCPMC12005175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.